This site is intended for health professionals only

B-MS drops co-operative HIV venture

teaser

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Sweden’s Medivir has been told that partner Bristol-Myers Squibb has terminated development of the firms’ preclinical HIV compound MIV-170.

The decision was taken “because the compound did not meet the profile desired” by the New York-based drugs major. The Swedish firm noted that MIV-170 belongs to a group






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x